NCT06676280

ASpirin Use and stAtin Strategy for Primary Prevention in Severe Coronary Calcium Score on Computed Tomography

an Investigator-initiated, Multicenter, Open-label, 2-by-2 Factorial, and Randomized Trial to Evaluate the Role of Aspirin and High-intensity Statin Therapy, Respectively, in Individuals With Severe Coronary Calcification (Coronary Calcium Score ≥300) to Prevent Atherosclerotic Cardiovascular Disease (ASCVD) Events With Severe Coronary Calcification (CAC ≥300)

• Status: Recruiting
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 5,000 (estimated)
• Sponsor: Jung-min Ahn · Academic / Other
• Sex: All
• Age: 40 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The primary objective of the ASA-3C trial is to evaluate the role of aspirin and high-intensity statin therapy, respectively, in individuals with severe coronary calcification (coronary calcium score ≥300) to prevent atherosclerotic cardiovascular disease (ASCVD) events with severe coronary calcification (CAC ≥300).

Conditions

• Cardiovascular Diseases

Interventions

Type	Name	Description
DRUG	Aspirin	Patients will take aspirin 100 mg/day.
DRUG	High-intensity statin	Statin intensity is defined as 2018 Cholesterol Clinical Practice Guidelines.
DRUG	Guideline-directed statin therapy	as 2018 Cholesterol Clinical Practice Guidelines.

Timeline

• Start date: 2025-07-24
• Primary completion: 2035-03-31
• Completion: 2035-12-31
• First posted: 2024-11-06
• Last updated: 2026-01-29

Locations

1 site across 1 country: South Korea